EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism

导出原文传递

翻译打印收藏纠错

作者： Liu, Sangtian ^[1] ; He, Yayi ^[2] ; Jiang, Tao ^[3] ; Ren, Shengxiang ; Zhou, Fei ; Zhao, Chao ; Li, Xuefei ; Zhang, Jie ; Su, Chunxia ; Chen, Xiaoxia ; Cai, Weijing ; Gao, Guanghui ; Li, Wei ; Wu, Fengying ; Li, Jiayu ; Zhao, Jing ; Hu, Qiong ; Zhao, Mingchuan ; Zhou, Caicun ; Hirsch, Fred R.

作者单位： Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Lung Canc & Immunol,Canc Inst, 507 Zhengmin Rd ^[1] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA ^[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol,Canc Inst, 507 Zhengmin Rd, Shanghai ^[3]

关键词 BIM deletion polymorphism Non-small-cell lung cancer Epidermal growth factor receptor mutation EGFR tyrosine kinase inhibitor Chemotherapy

发布时间 2019-01-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览3

Lung cancer

2018年120卷

82-87页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism

Lung cancer

相似文献

Lung cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism

Lung cancer

相似文献

Lung cancer

相关期刊

检索历史清除